| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bca3b113354c50e02fd69af5e5021250
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 |
| filingDate |
2018-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_398fbb1cb3a234d4641407c462b5a586
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8024259c21204e13c5495e0721936ddc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93e9160d7d8a474badab0a2e2387a17b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4600162f2386ce4cb38fbeff57393cab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dae8e1b19b987b01e3f8905a8d29d37 |
| publicationDate |
2019-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201902489-A |
| titleOfInvention |
Synergistic combination of nucleic acid oligonucleotides and nucleoside analog chemotherapeutic agents |
| abstract |
The present invention provides compositions and methods for treating cancer, the methods comprising administering a combination of anti-cancer agents, wherein the combination comprises a nucleoside analog chemotherapeutic agent and one or more splicing variants capable of down-regulating the IG20 gene The nucleic acid molecules that are expressed, and not all of the splice variants of the IG20 gene are down-regulated. In one embodiment, the splicing variant of the IG20 gene is a MADD splicing variant and the nucleic acid molecule comprises a nucleic acid sequence of exon 13L with a MADD splice variant or a mRNA transcription of exon 13L with a MADD splice variant siRNA, shRNA and antisense oligonucleotides of complementary nucleic acid sequences. The invention encompasses methods of treating cancer, the methods comprising a combination therapy of a nucleic acid molecule capable of downregulating the expression of at least one splicing variant of the IG20 gene and a nucleoside analog chemotherapeutic agent. |
| priorityDate |
2017-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |